Global Pharmaceutical R&D Outsourcing Market 2023-2029
Pharmaceutical R&D outsourcing is a strategy where a pharmaceutical company contracts the services of a third-party organisation to carry out some aspects of its research and development activities. This outsourcing strategy is used to reduce costs, improve efficiency, and increase the speed of drug development. Pharmaceutical R&D outsourcing can involve a wide range of activities, including clinical trial management, drug discovery, drug formulation, and regulatory affairs. Outsourcing to a specialised organisation can help a company to gain access to expertise and technology that it may not have in-house. The global pharmaceutical R&D outsourcing market size is projected to grow by USD 53.0 billion from 2023 to 2029, registering a CAGR of 8.6 percent, according to the latest market data.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pharmaceutical R&D outsourcing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, stage of development, organization size, therapy area, and region. The global market for pharmaceutical R&D outsourcing can be segmented by product: biologics, small molecules. The small molecules segment held the largest revenue share in 2022. Pharmaceutical R&D outsourcing market is further segmented by stage of development: clinical, non-clinical. Among these, the clinical segment was accounted for the highest revenue generator in 2022. Based on organization size, the pharmaceutical R&D outsourcing market is segmented into: large enterprises, small and medium enterprises (SMEs). The SMEs segment captured the largest share of the market in 2022. On the basis of therapy area, the pharmaceutical R&D outsourcing market also can be divided into: cardiovascular diseases, central nervous system disorders, gastrointestinal disorders, infectious diseases, musculoskeletal disorders, oncology, others. According to the research, the oncology segment had the largest share in the global pharmaceutical R&D outsourcing market. Pharmaceutical R&D outsourcing market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America held the largest revenue share in 2022.
Market Segmentation
By product: biologics, small molecules
By stage of development: clinical, non-clinical
By organization size: large enterprises, small and medium enterprises (SMEs)
By therapy area: cardiovascular diseases, central nervous system disorders, gastrointestinal disorders, infectious diseases, musculoskeletal disorders, oncology, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report has also analysed the competitive landscape of the global pharmaceutical R&D outsourcing market with some of the key players being Boehringer Ingelheim GmbH, Charles River Laboratories International, Inc., Hangzhou Tigermed Consulting Co., Ltd., ICON plc, IQVIA Holdings, Inc., Labcorp Drug Development Inc, Lonza Group AG, PAREXEL International Corporation, Pharmaron Inc., Samsung Biologics Co., Ltd., Syneos Health, Inc., Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Scope of the Report
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook